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Abstract: 
Alcoholic steatosis is a fundamental metabolic disorder in the progression of alcoholic liver 
disease. Zinc deficiency is one of the most consistently observed biochemical/nutritional 
manifestations of alcoholic liver disease. The purpose of this study is to determine whether 
dietary zinc supplementation to mice previously exposed to alcohol could reverse alcoholic 
steatosis. Male 129S mice were pair-fed an alcohol or isocaloric maltose dextrin liquid diet for 
16 weeks with or without dietary zinc supplementation for the last 4 weeks. Zinc 
supplementation significantly attenuated alcohol-mediated increases in hepatic triglyceride, 
cholesterol, and free fatty acids in association with accelerated hepatic fatty acid oxidation and 
very low density lipoproteins (VLDL) secretion. Hepatic genes related to fatty acid oxidation and 
VLDL secretion were up-regulated by zinc supplementation, which was accompanied by 
restoring activity of hepatocyte nuclear factor-4α (HNF-4α) and peroxisome proliferators 
activated receptor-α (PPAR-α). Zinc supplementation enhanced alcohol metabolism and 
attenuated oxidative stress and liver injury. Zinc supplementation also normalized alcohol-
mediated increases in plasma triglycerides and partially reversed decrease in gonadal adipose 
depot mass. Studies in HepG2 cells showed that zinc deprivation significantly suppressed the 
DNA-binding activities of HNF-4α and PPAR-α, and reduced HNF-4α and PPAR-α target 
proteins. Consequently, zinc deprivation caused cellular accumulation of lipid droplets, 
triglycerides and free fatty acids in the HepG2 cells. Conclusion: Zinc supplementation reverses 
alcoholic steatosis, and reactivation of HNF-4α and PPAR-α by increasing zinc availability and 
inhibiting oxidative stress are potential mechanisms underlying these beneficial effects of zinc on 
hepatic lipid homeostasis. 
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Article: 
Alcoholic steatosis (fatty liver) is one of the earliest pathological changes in alcoholic liver 
disease, and accumulation of lipid in the hepatocyte makes the liver susceptible to inflammatory 
mediators or other toxic agents, potentially leading to hepatitis and eventually 
fibrosis.1 Alcoholic steatosis is a reversible stage of liver damage, and reduction of steatosis will 
likely halt or slow the progression of alcoholic liver disease. Although previous studies have 
shown that alterations in hepatic fatty acid synthesis, fatty acid oxidation, and triglyceride-rich 
very low density lipoprotein (VLDL) secretion are involved the pathogenesis of alcoholic 
steatosis,2–4 the molecular mechanisms underlying the alcohol effects on hepatic lipid 
homeostasis have not been fully defined. 
Zinc deficiency is one of the most consistently observed nutritional/biochemical manifestations 
in alcoholic liver disease.5 Clinical studies demonstrated that zinc concentrations in both serum 
and liver were significantly reduced in patients with alcoholic steatosis, hepatitis, and cirrhosis.6–
8 Animal studies showed that dietary zinc supplementation attenuates alcohol-induced liver 
injury,9–13 suggesting the importance of zinc in progression of alcoholic liver disease. Although 
the link between zinc and alcoholic steatosis has not been determined, increasing evidence 
suggest that zinc plays a critical role in regulation of hepatic lipid metabolism. A lower hepatic 
zinc level was associated with steatosis in rats with a leptin receptor deficiency.14 Feeding rats 
with a zinc-deficient diet (a single-nutrient deficiency) causes hepatic lipid accumulation in 
association with dysregulation of a large number of genes involved in lipid metabolism.15–17 
Given the fact that dietary zinc deficiency modifies the lipid metabolic gene profile to facilitate 
hepatic lipid accumulation, and given the evidence that alcohol causes hepatic zinc deficiency, 
we postulated that zinc supplementation would provide beneficial effects toward alcoholic 
steatosis. The present study was undertaken to determine whether or not dietary zinc 
supplementation can reverse alcohol-induced steatosis in mice previously exposed to alcohol. 
Peroxisome proliferator-activated receptor-α (PPAR-α) and hepatocyte nuclear factor-4α (HNF-
4α) are known as the key regulators in hepatic fatty acid β-oxidation and VLDL secretion,18–
20 and both PPAR-α and HNF-4α are zinc finger transcription factors. To define potential 
mechanisms of zinc action, the link between zinc and HNF-4α and PPAR-α was also evaluated. 
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Materials and Methods 
Animals and Alcohol Feeding Experiments. 
Male 129S mice were obtained from Harlan (Indianapolis, IN). All the mice were treated 
according to the experimental procedures approved by the Institutional Animal Care and Use 
Committee. The mice were pair-fed the Lieber-DeCarli alcohol liquid diet (Bio-Serv, 
Frenchtown, NJ), containing either ethanol (EtOH) or isocaloric maltose dextrin as control (Ctrl) 
for 12 weeks to produce liver injury as described previously.11 The mice were then divided into 
four groups: (1) Ctrl, (2) EtOH, (3) Zn, and (4) EtOH+Zn, and continually fed for 4 weeks. For 
zinc supplementation, zinc sulfate was added to the liquid diet at 75 mg elemental Zn/L as 
described.9, 11 At the end of the feeding experiment, the mice were anesthetized with Avertin 
(300 mg/kg body weight) after 4 hours fasting, and plasma, liver, and gonadal adipose depot 
(GAD) samples were harvested for assays. 
HepG2 Cell Culture. 
HepG2 cells obtained from the American Type Culture Collection (Manassas, VA) were grown 
in Dulbecco's modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum and penicillin (100 U/mL)/streptomycin sulfate (100 μg/mL) 
(Invitrogen, Carlsbad, CA). To evaluate the role of zinc in HNF-4α and PPAR-α functions and in 
hepatic lipid metabolism, zinc deprivation was induced by adding N,N,N′,N′-tetrakis (2-
pyridylmethyl) ethylenediamine (TPEN) at a final concentration of 2 μM, and cells were cultured 
for 4 days. Zinc sulfate was added at 25 and 50 μM elemental zinc 2 hours after TPEN treatment 
to confirm the specificity of the zinc-chelating action of TPEN. 
Blood Metabolites Assay. 
Plasma zinc concentrations were determined by inductively coupled argon plasma emission 
spectroscopy. Alcohol concentrations were determined using an Ethanol Assay Kit (BioVison, 
Mountain View, CA). Alanine aminotransferase (ALT) activities were measured with an Infinity 
ALT kit (Thermo Scientific, Waltham, MA). Plasma triglyceride and cholesterol concentrations 
were measured using the Infinity Triglyceride Reagent and Infinity Cholesterol Reagent (Thermo 
Scientific), respectively. Plasma free fatty acid concentrations were determined with a Free Fatty 
Acid Quantification Kit (BioVision). Blood β-hydroxybutyrate (ketone) was determined using a 
CardioCheck analyzer with PTS Panels ketone test strips (Polymer Technology Systems, 
Indianapolis, IN). Blood glucose was measured using a OneTouch Ultra2 blood glucose meter 
(Life Scan, Milpitas, CA). 
Determination of Lipid Accumulation and Liver Injury. 
Oil red O staining of neutral lipid was performed on cryostat liver sections and chamber slides of 
HepG2 cells. Quantitative assay of lipids was conducted by measuring the concentrations of 
triglycerides, cholesterol, and free fatty acids in the liver tissue and hepatocytes as described 
above. To assess liver injury, liver tissue sections were prepared and stained with hematoxylin 
and eosin. 
Hepatic Fatty Acid β-Oxidation Assay. 
Hepatic fatty acid β-oxidation activity was measured as described.21 Briefly, 100 mg liver was 
homogenized in nine volumes of cold 10 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic 
acid (HEPS) (pH 7.2) containing 300 mM mannitol and 0.1 mM ethylene glycol tetraacetic acid. 
The homogenates were centrifuged at 600g for 10 minutes, and the resulting supernatants were 
used. Fatty acid β-oxidation was assayed as palmitoyl-coenzyme A (CoA)–dependent oxidized 
nicotinamide adenine dinucleotide (NAD+) reduction by using an assay mixture containing 50 
mM potassium phosphate, 0.5 mM NAD+, 0.2 mM CoA, 1 mM dithiothreitol, and 0.005% 
(wt/wt) Triton X-100 (pH 8.2). The reaction was started by addition of 50 μM palmitoyl-CoA, 
and the reduction of NAD+ was recorded at 340 nm. 
Estimation of Hepatic Lipid Export. 
Hepatic VLDL triglyceride production was determined with the Triton WR1339 method as 
described.22 In brief, mice after an overnight fast were anesthetized with Avertin (300 mg/kg 
body weight), and injected via tail vein with Triton WR1339 solution (Tyloxapol; Sigma 
Chemicals, St. Louis, MO) at 500 mg/kg body weight. Prior to injection and at 90 minutes after 
Triton WR1339 injection, 40 μL of blood was drawn by retro-orbital bleeding, and plasma was 
separated and measured for triglyceride concentration. The hepatic VLDL triglyceride secretion 
rate was expressed as milligram per gram of liver per hour. 
Real-Time Reverse Transcription Polymerase Chain Reaction Assay. 
The total RNA was isolated and reverse transcribed with the Moloney murine leukemia virus 
reverse transcriptase and oligo-deoxythymidine primers. The forward and reverse primers were 
designed using Primer Express Software and listed in Table 1. The SYBR green polymerase 
chain reaction (PCR) Master Mix (Applied Biosystems, Foster City, CA) was used for real-time 
reverse transcription PCR (RT-PCR) analysis. The relative differences of gene expression among 
groups were evaluated using cycle time values. The data were normalized to 18S and expressed 
as relative changes, setting the values of control mice as one. 
Table 1. Primer Sequences for Real-Time RT-PCR 
Gene GenBank 
Accession No. 
Sequences (Forward/Reverse) 
Acadl NM_007381 GGCTTGCTTGGCATCAACA 
GAGTACGCTTGCTCTTCCCAAGT 
ApoB BC100607 GCGTCTGGGCTCAAGATGAA 
ACACGTACTTTCGGAGGTGCTT 
Cpta1 NM_013495 CCTGGGCATGATTGCAAAG 
ACGCCACTCACGATGTTCTTC 
HNF4a NM_008261 CGGAGCCCCTGCAAAGT CCAGTCTCACAGCCCATTCC 
Mttp NM_008642 TCAAGAGAGGCTTGGCTAGCTT 
GCCTGGTAGGTCACTTTACAATCC 
Ppara X89577 CCATACAGGAGAGCAGGGATTT 
TTACCTACGCTCAGCCCTCTTC 
Adh1 M22611 GGCCGCCTTGACACCAT 
GCACTCCTACGACGACGCTTA 
Adh4 NM_011996 GCAGTCCCCTTTGCATTGAA 
CGTGGCGATTACCTGAATCC 
Adh5 NM_007410 GGCAACGTGAAGGTCATGAGA 
GCTACTCCCACTACCACACTGACA 
Aldh2 NM_009656 AGCCAATTACCTGTCCCAAGCT 
AGACTGGGCCCCAAACACA 
18S X56974 CGAACGTCTGCCCTATCAACTT 
CCGGAATCGAACCCTGATT 
 
HNF-4α and PPAR-α DNA Binding Assay. 
Nuclear extracts from mouse liver and HepG2 cells were prepared using a kit from Active Motif 
(Carlsbad, CA). The HNF-4α and PPAR-α function was assessed by measuring the DNA-
binding ability with a Trans-AM HNF Family Transcription Factor enzyme-linked 
immunosorbent assay (ELISA) kit from Active Motif (Carlsbad, CA) and a PPAR-α 
Transcription Factor ELISA kit from Cayman Chemical (Ann Arbor, MI), respectively. Each kit 
consists of a 96-well plate into which a specific oligonucleotide sequence containing the 
consensus site of HNF-4α or PPAR-α is immobilized. The HNF-4α or PPAR-α bound to the 
consensus site is recognized by a rabbit polyclonal antibody against HNF-4α or PPAR-α, 
followed by incubation with a horseradish peroxidase–conjugated secondary antibody for the 
colorimetric quantification. 
Measurement of Hepatic Oxidative Stress. 
The activities of superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase were 
measured using assay kits from Cayman Chemical (Ann Arbor, MI). The lipid peroxidation 
product, malondialdehyde, was measured as thiobarbituric acid reactive substances (TBARS) 
with a Cayman TBARS kit. 
Immunoblotting Analysis. 
Aliquots containing 30 μg protein were loaded onto a 8%-12% sodium dodecyl sulfate–
polyacrylamide gel. After electrophoresis, proteins were transferred to a polyvinylidene fluoride 
membrane. The membrane was probed with rabbit or goat polyclonal antibodies against HNF-
4α, PPAR-α, medium-chain acyl-CoA dehydrogenase (ACADM), microsomal triglyceride 
transfer protein (MTTP), apolipoprotein B (ApoB), Cu/Zn-SOD, GPx (Santa Cruz 
Biotechnologies, Santa Cruz, CA), long-chain acyl-CoA dehydrogenase (ACADL; Proteintech, 
Chicago, IL), or very long-chain acyl-CoA dehydrogenase (ACADVL; Novus Biologicals, 
Littleton, CO). The membrane was then processed with horseradish peroxidase–conjugated 
donkey anti-rabbit immunoglobulin G or donkey anti-goat immunoglobulin G (GE Healthcare, 
Piscataway, NJ). The protein bands were visualized by an Enhanced Chemiluminescence 
detection system (GE Healthcare) and quantified by densitometry analysis. 
Statistics. 
All data are expressed as mean ± standard deviation (n = 4-6). The data were analyzed by 
analysis of variance (ANOVA) and Newman-Keuls' Multiple-Comparison Test. Differences 
between groups were considered significant at P < 0.05. 
Results 
Effects of Zinc Supplementation on Body Weight, Liver Weight, GAD Weight, and Plasma 
Metabolites. 
After 16 weeks of alcohol exposure, mice showed a significantly lower body weight and body 
weight gain compared to the pair-fed controls (Table 2). Zinc supplementation for the last 4 
weeks did not significantly affect the body weight and body weight gain in either alcohol-fed or 
pair-fed mice. Alcohol exposure significantly increased the liver/body weight ratio, which was 
normalized by zinc supplementation. In contrast to an increase in liver/body weight ratio, a 
significant decrease in GAD/body weight ratio was found in alcohol-fed mice due to a dramatic 
decrease in GAD weight. Zinc supplementation partially reversed the alcohol-reduced 
GAD/body weight ratio. 
Table 2. Effects of Chronic Alcohol Exposure and Zinc Supplementation on Body Weight, Liver 
Weight, Epididymal White Adipose Tissue Weight, and Blood Metabolites 
Characteristic Ctrl EtOH Zn EtOH/Zn 
Body weight (g)         
 Initial 26.4 ± 0.5 26.3 ± 0.7 26.6 ± 0.8 26.4 ± 0.3 
 End 31.6 ± 0.5a 28.2 ± 1.5b 33.1 ± 1.4a 28.3 ± 0.8b 
 Gain 5.2 ± 0.4a 1.9 ± 1.0b 6.5 ± 0.7a 1.8 ± 0.7b 
Liver weight (g) 1.24 ± 0.422ab 1.33 ± 0.07a 1.36 ± 0.10a 1.18 ± 0.73b 
Liver/body weight ratio 3.93 ± 0.15a 4.72 ± 0.33b 4.11 ± 0.27a 4.17 ± 0.21b 
GAD weight (g) 1.31 ± 0.17a 0.23 ± 0.04b 1.34 ± 0.03a 0.59 ± 0.13c 
GAD/body weight ratio 4.15 ± 0.47a 0.84 ± 0.16b 4.06 ± 0.22a 2.02 ± 0.43c 
Blood metabolites         
 Zinc (μg/dL) 79.3 ± 2.9a 67.6 ± 3.6b 75.1 ± 3.6a 77.4 ± 6.5a 
 Alcohol (mg/dL) NA 30.6 ± 8.2a NA 15.5 ± 3.9b 
 ALT activity (U/L) 27.9 ± 5.3a 78.0 ± 6.3b 26.7 ± 7.6a 54.8 ± 7.7c 
 Triglyceride (mg/dL) 97 ± 7a 174 ± 15b 113 ± 16a 145 ± 15c 
 Cholesterol (mg/dL) 113 ± 13a 93 ± 13b 116 ± 14a 121 ± 12a 
 Free fatty acids (mg/dL) 26.6 ± 1.8 24.8 ± 4.4 24.6 ± 2.9 21.5 ± 1.4 
 β-hydroxybutyrate (mg/dL) 5.6 ± 1.2a 11.8 ± 3.4b 8.2 ± 2.7ab 17.8 ± 2.6c 
 Glucose (mg/dL) 145 ± 16a 106 ± 14b 153 ± 30a 110 ± 15b 
Mice were pair-fed alcohol or isocaloric maltose dextrin for 16 weeks with or without zinc 
supplementation for the last 4 weeks. 
Results are means ± SD (n = 4–6). Significant differences (P < 0.05) among a, b, and c are 
determined by ANOVA. 
ALT, alanine aminotransferase; Ctrl, control; EtOH, ethanol; GAD, gonadal adipose depot; Zn, 
zinc. 
Alcohol exposure caused a significant decrease in the plasma zinc level, which was normalized 
by zinc supplementation. The plasma alcohol levels of alcohol-fed mice after zinc 
supplementation were lower than alcohol without zinc. The plasma ALT activities, an indicator 
of liver injury, were elevated with alcohol exposure, and this rise was attenuated by zinc 
supplementation. Alcohol exposure elevated the levels of plasma triglyceride and β-
hydroxybutyrate, and decreased plasma cholesterol, but did not affect the level of plasma free 
fatty acids. Zinc supplementation significantly reduced the elevations in plasma triglycerides and 
normalized plasma cholesterol. On the other hand, zinc supplementation to alcohol-fed mice 
further increased the blood β-hydroxybutyrate in comparison with alcohol alone. Alcohol 
exposure also decreased the plasma glucose, and this reduction was not influenced by zinc 
supplementation. 
Zinc Supplementation Partially Attenuated Alcohol-Induced Lipid Accumulation and 
Liver Injury. 
Oil Red O stain demonstrated that alcohol exposure caused lipid droplet accumulation in the 
liver (Fig. 1A). Zinc supplementation to alcohol-fed mice remarkably reduced the number and 
the size of lipid droplets in the liver. Quantitative assay of hepatic lipid content showed alcohol 
exposure caused remarkable increases in hepatic triglyceride (Fig. 1B), cholesterol (Fig. 1C), and 
free fatty acids (Fig.1D), which were significantly reduced by zinc supplementation. In 
accordance with the plasma ALT activity (Table 2), zinc supplementation attenuated alcohol-
induced liver pathological changes, including neutrophil infiltration and necrotic cell death. 
 
Figure 1. Hepatic lipid accumulation in mice fed alcohol for 16 weeks with or without zinc 
supplementation for the last 4 weeks. (A) Oil red O staining of the neutral lipid in the liver. (B) Hepatic 
triglyceride. (C) Hepatic cholesterol. (D) Hepatic free fatty acids (FFAs). Results are means ± standard 
deviation (SD) (n = 4–6). Significant differences (P < 0.05) among “a”, “b”, and “c” are determined by 
ANOVA. Ctrl, control; EtOH, ethanol; Zn, zinc. 
Zinc Supplementation Accelerated Hepatic Fatty Acid β-Oxidation and Lipid Export. 
To understand the possible mechanism by which zinc supplementation attenuates alcohol-
induced lipid accumulation in the liver, the effects of zinc supplementation on hepatic fatty acid 
β-oxidation and lipid export were determined. Hepatic fatty acid β-oxidation was not affected by 
alcohol exposure, but was accelerated by zinc supplementation (Fig. 2A). The VLDL export 
capacity was estimated by measuring VLDL triglyceride secretion to the blood after blocking 
lipolysis of lipoproteins by Triton WR1339. Alcohol exposure caused a decrease in VLDL 
triglyceride secretion, which was normalized by zinc supplementation (Fig. 2B). 
 
Figure 2. Hepatic fatty acid oxidation and VLDL secretion in mice fed alcohol for 16 weeks with or 
without zinc supplementation for the last 4 weeks. (A) Hepatic fatty acid β-oxidation. (B) Hepatic VLDL-
TG (triglyceride) secretion rate measured by the Triton WR1339 method. (C) Real-time RT-PCR assay of 
genes related to fatty acid β-oxidation and VLDL secretion. Results are means ± SD (n = 4–6 in (A) and 
(B); n = 4 in (C)). Significant differences (P < 0.05) between “a” and “b” are determined by ANOVA. 
Ctrl, control; EtOH, ethanol; Zn, zinc. 
To determine how zinc supplementation modulates lipid metabolism, hepatic genes involved in 
fatty acid β-oxidation (Cpt1a and Acadl) and VLDL secretion (Mttp and Apob) were measured. 
the Cpt1a messenger RNA (mRNA) was significantly decreased by alcohol exposure, and zinc 
supplementation did not alter the alcohol effect (Fig. 2C). The mRNA levels of Acadl, Mttp, and 
ApoB were not affected by alcohol exposure, but were significantly increased by zinc 
supplementation. 
Zinc Supplementation Reversed Alcohol-Inactivated Hepatic HNF-4α and PPAR-α. 
To determine if zinc action is related to HNF-4α and PPAR-α, the mRNA, protein, and DNA-
binding activity of HNF-4α and PPAR-α were measured. The mRNA levels of HNF-4α and 
PPAR-α were not affected by alcohol exposure, but were significantly increased by zinc 
supplementation (Fig. 3). Alcohol exposure did not affect the HNF-4α protein but decreased the 
PPAR-α protein, and zinc supplementation normalized alcohol-reduced PPAR-α protein level. 
The DNA-binding activities of HNF-4α and PPAR-α were significantly diminished by alcohol 
exposure, which was partially recovered by zinc supplementation. 
 
Figure 3. Hepatic HNF-4α and PPAR-α status in mice fed alcohol for 16 weeks with or without zinc 
supplementation for the last 4 weeks. Protein and mRNA levels and activation of (A) HNF-4α and (B) 
PPAR-α measured by real-time RT-PCR, immunoblotting, and DNA-binding ELISA, respectively. The 
immunoblotting bands were quantified by densitometry analysis and the ratio to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was calculated by setting the value of controls as one. Results are 
means ± SD (n = 4–6). Significant differences (P < 0.05) among “a”, “b”, and “c” are determined by 
ANOVA. Ctrl, control; EtOH, ethanol; Zn, zinc. 
Zinc Supplementation Enhanced Enzymes Involved in Antioxidant Defense and Alcohol 
Metabolism. 
Oxidative stress has been shown to inactivate zinc finger transcription factors by mobilizing zinc. 
To determine if inhibition of oxidative stress is associated with the zinc action, the major cellular 
antioxidant enzymes Cu/Zn-SOD, GPx, and catalase, and the lipid peroxidation product 
malondialdehyde, were measured. No differences in Cu/Zn-SOD protein levels were found 
among the treatments (Fig. 4A). However, the SOD activity was significantly reduced by alcohol 
exposure, which was normalized by zinc supplementation. Zinc supplementation did not affect 
the protein level of GPx, but increased the GPx activity (Fig. 4B). Alcohol exposure decreased 
the catalase activity, which was attenuated by zinc supplementation (Fig. 4C). As an indicator of 
oxidative stress, the lipid peroxidation product malondialdehyde was significantly increased by 
alcohol exposure, and this increase was significantly inhibited by zinc supplementation 
(Fig. 4D). To determine if modulation of alcohol metabolism is involved in zinc action, the 
expression of hepatic alcohol dehydrogenase class I (Adh1), II (Adh4), and III (Adh5), and 
mitochondrial aldehyde dehydrogenase (Aldh2) were measured. Zinc supplementation up-
regulated expression of Adh1, adh5, and Aldh2, and normalized expression of Adh4 (Fig. 4E). 
 
Figure 4. Hepatic antioxidant capacity and alcohol metabolic genes in mice fed alcohol for 16 weeks with 
or without zinc supplementation for the last 4 weeks. Protein and/or activities of (A) Cu/Zn-SOD, (B) 
GPx, and (C) catalase. The bands in (A) and (B) were quantified by densitometry analysis and the ratio to 
GAPDH was calculated by setting the value of controls as one. *Significantly different from other groups. 
(D) Malondialdehyde (MDA) concentrations. (E) Real-time RT-PCR assay of alcohol metabolic genes. 
Results are means ± SD (n = 4–6). Significant differences (P < 0.05) among “a”, “b”, and “c” are 
determined by ANOVA. Ctrl, control; EtOH, ethanol; Zn, zinc. 
In Vitro Zinc Deprivation Impaired HNF-4α and PPAR-α Function and Lipid Homeostasis 
in HepG2 Cells. 
The effects of zinc deprivation by TPEN on HNF-4α and PPAR-α and their target proteins as 
well as cellular lipid accumulation were determined in HepG2 cell culture. Immunoblotting 
analysis showed that zinc deprivation with or without zinc supplementation did not significantly 
affect the protein levels of HNF-α (Fig. 5A) and PPAR-α (Fig. 5B). However, the DNA-binding 
activities of HNF-4α (Fig. 5C) and PPAR-α (Fig. 5D) were significantly decreased by zinc 
deprivation. HNF-4α and PPAR-α regulatory proteins related to fatty acid β-oxidation (ACADM, 
ACADL, ACADVL) and VLDL secretion (MTTP, ApoB) were further determined by 
immunoblotting analysis, and zinc deprivation reduced the protein levels of ACADL, MTTP, 
and ApoB (Fig. 5E). Oil red O stain showed that zinc deprivation caused lipid droplet 
accumulation in the HepG2 cells (Fig. 6A). Zinc deprivation significantly increased the cellular 
concentrations of triglycerides (Fig. 6B) and free fatty acids (Fig. 6C). Zinc supplementation 
reversed of all the effects of TPEN, indicating that TPEN specifically induces zinc deprivation. 
 
Figure 5. Effect of zinc deprivation on HNF-4α and PPAR-α function in HepG2 cell culture. HepG2 cells 
were treated with TPEN at 2 μM with or without zinc supplementation at 25 or 50 μM for 4 days. 
Immunoblotting analysis of HNF-4α (A) and PPAR-α (B) protein. DNA binding activity of HNF-4α (C) 
and PPAR-4α (D). (E) Immunoblotting of HNF-4α and PPAR-α target proteins. The bands were 
quantified by densitometry analysis and the ratio to GAPDH was calculated by setting the value of 
controls as one. Results in (C) and (D) are means ± SD (n = 4). Significant differences (P < 0.05) between 
“a” and “b” are determined by ANOVA. Ctrl, control; EtOH, ethanol; Zn, zinc. 
 
Figure 6. Effect of zinc deprivation on cellular lipid accumulation in HepG2 cell culture. HepG2 cells 
were treated with TPEN at 2 μM with or without zinc supplementation at 25 or 50 μM for 4 days. (A) Oil 
red O staining of neutral lipid. (B) Triglyceride concentrations. (C) Free fatty acids (FFAs) 
concentrations. Results are means ± SD (n = 4). Significant differences (P < 0.05) between “a” and “b” 
are determined by ANOVA. Ctrl, control; T, TPEN. 
Discussion 
The present study demonstrates that zinc supplementation reverses alcohol-induced steatosis in 
part by stimulating fatty acid oxidation and VLDL secretion. Reactivation of HNF-4α and 
PPAR-α represent one mechanism for the observed beneficial effects of zinc on fatty acid 
oxidation and VLDL secretion. Inhibition of oxidative stress by zinc is associated with 
reactivation of these zinc finger transcription factors. The antioxidant action of zinc most likely 
resulted from the enhancement of antioxidant enzymes. Furthermore, accelerated alcohol 
clearance by zinc may lead to reduction of hepatic reactive alcohol metabolites which can release 
zinc from zinc proteins. Cell culture studies further validated the link between zinc and HNF-4α 
and PPAR-α in lipid metabolism. Zinc deprivation significantly suppressed the DNA-binding 
activities of HNF-4α and PPAR-α, and led to lipid accumulation in HepG2 cells. These results 
thus indicate that zinc deficiency may play a critical role in the pathogenesis of alcohol-induced 
steatosis by inactivating HNF-4α and PPAR-α. Furthermore, zinc supplementation normalized 
alcohol-elevated plasma triglycerides and partially reversed alcohol-reduced epididymal white 
adipose tissue, suggesting that reversal of adipose tissue lipolysis may also be involved in the 
beneficial effects of zinc on alcohol-induced steatosis. 
Zinc finger transcription factors represent one of the largest classes of DNA-binding proteins, 
and elimination of zinc coordination by reactive oxygen species or iron from the zinc finger can 
disassemble the secondary structure of these proteins, leading to defective DNA binding and 
decreased transcription of target genes.23–26 The present study showed that zinc supplementation 
reactivates the suppressed DNA binding activity of both HNF-4α and PPAR-α caused by alcohol 
exposure. Zinc is known to have antioxidant properties.27 Indeed, this study showed that zinc 
supplementation preserves the major hepatic antioxidant enzymes, SOD, GPx, and catalase, 
which may account for zinc inhibition of alcohol-induced reactive oxygen species and lipid 
peroxidation products accumulation in the liver.11 In addition, zinc supplementation also 
normalizes or up-regulates alcohol metabolic enzymes, thereby enhancing alcohol clearance. 
Because acetaldehyde, the major toxic metabolite of alcohol metabolism, has been shown to 
release zinc from zinc proteins,28 accelerated alcohol clearance may also contribute to zinc 
restoration of alcohol-inactivated PPAR-α and HNF-4α. Although dietary zinc deficiency has 
been shown to interfere with lipid metabolism,15–17 this study demonstrates that dysfunction of 
PPAR-α and HNF-4α may account for the deleterious effects of zinc deficiency on lipid 
metabolism. 
PPAR-α and HNF-4α belong to the nuclear hormone superfamily and play an important role in 
regulation of hepatic lipid homeostasis, in particular fatty acid β-oxidation and VLDL secretion, 
respectively. PPAR-α is one of the most well-recognized transcription factors in mechanistic 
studies on the pathogenesis of alcoholic steatosis.3, 19, 20 The effects of chronic alcohol exposure 
on hepatic PPAR-α mRNA are controversial; some studies reported a decrease,29 whereas others 
showed no change.30, 31 Chronic alcohol exposure in mice has been reported to suppress the 
DNA-binding activity of PPAR-α, without affecting the protein level.31 Treatment with the 
PPAR-α agonist WY14,643 up-regulated PPAR-α mRNA and increased the PPAR-α 
protein.31 Importantly, WY14,643 treatment to alcohol-fed mice increased the DNA-binding 
activity in association with up-regulation of many PPAR-α target genes; in particular, the fatty 
acid β-oxidation–related genes. Treatment with the PPAR-α agonist clofibrate in chronic 
alcohol-fed rats also remarkably reduced alcoholic steatosis.32 These studies clearly 
demonstrated that dysfunction of PPAR-α is an etiologic factor in the development of alcoholic 
steatosis. The results in this study showed that reactivation of PPAR-α is associated with zinc 
effects on alcoholic steatosis. The cell culture study further showed that zinc coordination is 
required for the DNA-binding activity of PPAR-α; this may explain how alcohol reduces PPAR-
α DNA-binding activity without affecting its protein level, an unsolved question raised from 
previous studies.31 
HNF-4α is a master regulator of hepatic gene expression,32 and it has been shown to bind to the 
reporters of more than 1200 genes involved in most aspects of hepatocyte function.33 Liver-
specific conditional knockout of HNF-4α in adult mice led to severe steatosis in association with 
disruption of expression of genes involved in VLDL secretion.18 Chronic alcohol exposure has 
been shown to inhibit VLDL synthesis and secretion rate.34–36 This study demonstrates a link 
between zinc and HNF-4α and VLDL secretion. Because alcohol exposure decreased the DNA-
binding activity of HNF-4α without affecting its protein level, the alcohol effect on HNF-4α is 
likely at the post-transcriptional level. Zinc supplementation up-regulated HNF-4α mRNA and 
restored DNA-binding activity of HNF-4α but did not affect the HNF-4α protein. These results 
suggest that alcohol exposure inactivates HNF-4α, at least partially through mobilizing zinc from 
HNF-4α, and zinc may regulate HNF-4α at both the transcriptional and post-transcriptional 
levels. Importantly, we also found that reactivation of HNF-4α by zinc supplementation is 
accompanied by up-regulation of genes involved in both VLDL secretion (Mttp, Apob) and fatty 
acid β-oxidation (Acadl). 
Previous studies have shown that alcohol exposure not only causes lipid accumulation in the 
liver, but also increases blood triglyceride and free fatty acids.31, 37 Alcohol exposure also 
decreases the epididymal white adipose tissue mass by increasing triglyceride degradation in 
adipose tissue, leading to increased release of free fatty acids into the circulation.38 Therefore, 
dysregulation of lipid homeostasis in both liver and adipose tissue may be involved in the 
development of alcoholic steatosis. Indeed, this study demonstrates that reversal of alcoholic 
steatosis is associated with zinc actions in both the liver and adipose tissue. First, zinc 
supplementation increased hepatic fatty acid β-oxidation. Second, zinc supplementation 
increased hepatic VLDL secretion but normalized alcohol-elevated plasma triglyceride. Third, 
zinc supplementation partially reversed alcohol-reduced GAD weight. These results indicate that 
reduction by zinc of the alcohol-induced hepatic lipid accumulation may involve at least two 
mechanisms: (1) acceleration of hepatic lipid utilization and export and (2) promotion of lipid 
deposition and/or inhibiting lipolysis in the adipose tissue. 
In conclusion, this study demonstrates that dietary zinc supplementation reverses alcoholic 
steatosis in mice previously exposed to alcohol by enhancing fatty acid β-oxidation and VLDL 
secretion. Alcohol exposure reduces the DNA-binding activity of HNF-4α and PPAR-α at least 
partially through mobilizing zinc from these zinc finger transcription factors. Reactivation of 
HNF-4α and PPAR-α is likely the most important molecular mechanism underlying the zinc 
action on lipid homeostasis. Furthermore, reversal of alcohol-reduced white adipose tissue mass 
may also be directly related to zinc reduction of hepatic lipid accumulation. These results suggest 
that zinc acts through multiple pathways to provide therapeutic efficacy in alcoholic steatosis. 
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